For sufferers with relapsed or refractory a number of myeloma (RRMM), triplet remedy of belantamab mafodotin (belamaf) plus bortezomib and dexamethasone (BVd) improves outcomes, with an appropriate security profile, based on a examine offered throughout the February 2024 session of the American Society for Medical Oncology Plenary Collection.
Maria-Victoria Mateos, Ph.D., from the Hospital Universitario de Salamanca in Spain, and colleagues performed a randomized, part III head-to-head trial to look at the efficacy and security of BVd versus triplet standard-of-care remedy (daratumumab, bortezomib, and dexamethasone [DVd]) for sufferers with RRMM. A complete of 494 sufferers with a number of prior strains of remedy had been randomly allotted to BVd or DVd (243 and 251, respectively); the first finish level was impartial evaluation committee-assessed progression-free survival (PFS).
The researchers discovered that the median PFS was 36.6 and 13.4 months within the BVd and DVd arms, respectively, after a median follow-up of 28.2 months (hazard ratio, 0.41). Total survival knowledge had been 29 % mature; median general survival was not reached in both arm (hazard ratio, 0.57).
The general response fee was 82.7 and 71.3 % for BVd and DVd, respectively. All sufferers skilled a number of antagonistic occasion; 90 and 67 % of sufferers, respectively, within the BVd and DVd arms reported grade 3/4 treatment-related antagonistic occasions, and 50 and 37 %, respectively, reported severe antagonistic occasions.
“The DREAMM-7 findings reveal that BVd improved outcomes for sufferers with relapsed or refractory a number of myeloma whereas additionally having a manageable security profile,” Mateos stated in a press release. “These outcomes assist BVd triplet remedy as a possible new normal of care possibility for these sufferers.”
One creator disclosed ties to pharmaceutical corporations, together with GlaxoSmithKline, which manufactures belamaf and funded the examine.
Extra info:
Press Launch
Extra Data
Copyright © 2024 HealthDay. All rights reserved.
Quotation:
Triplet remedy together with belamaf prolongs survival in a number of myeloma (2024, February 10)
retrieved 10 February 2024
from
This doc is topic to copyright. Other than any honest dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for info functions solely.